Friday’s Midday Stock Update: Brainstorm Cell Therapeutics (BCLI), Novavax (NVAX), Karyopharm Therapeutics (KPTI), Teva Pharmaceutical Industries (TEVA), Marathon Oil (MRO)

So far Friday, February 14, NASDAQ is down -3.06% and the S&P is down -0.63%. Here are this morning’s most active stocks: Brainstorm Cell Therapeutics (BCLIResearch Report), Novavax (NVAXResearch Report), Karyopharm Therapeutics (KPTIResearch Report), Teva Pharmaceutical Industries (TEVAResearch Report) and Marathon Oil (MROResearch Report).

Brainstorm Cell Therapeutics is down -9.22% in midday trading to $5.19. Shares opened today at $5.72. The company has a 52-week low of $3.43 and a 52-week high of $6.67. On the Street’s front, the average 12-month analyst price target for the stock is $9.00, marking a 57.34% potential upside from current levels. In a report issued on November 20, Maxim Group analyst Jason McCarthy maintained a Buy rating on BCLI, with a price target of $9.00, which implies an upside of 57% from current levels. Over the last 3 months, the insider sentiment on Brainstorm Cell Therapeutics has been positive based on 8 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Novavax is down -6.54% in midday trading to $7.52. Shares opened today at $8.05. The company has a 52-week low of $3.54 and a 52-week high of $44.20. On the Street’s front, the average 12-month analyst price target for the stock is $17.38, marking a 115.90% potential upside from current levels. In a report issued on January 27, Ladenburg Thalmann analyst Michael Higgins maintained a Buy rating on NVAX, with a price target of $27.50, which represents a potential upside of 242% from where the stock is currently trading. Over the last 3 months, the insider sentiment on Novavax has been negative based on 10 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Karyopharm Therapeutics is down -6.31% in midday trading to $15.37. Shares opened today at $16.40. The company has a 52-week low of $3.92 and a 52-week high of $20.09. On the Street’s front, the average 12-month analyst price target for the stock is $28.50, marking a 73.78% potential upside from current levels. In a report released today, H.C. Wainwright analyst Edward White reiterated a Buy rating on KPTI, with a price target of $40.00, which represents a potential upside of 144% from where the stock is currently trading. Separately, on January 21, Wedbush’s David Nierengarten downgraded the stock to Hold .

See today’s analyst top recommended stocks >>

Teva Pharmaceutical Industries is down -4.67% in midday trading to $12.16. Shares opened today at $12.75. The company has a 52-week low of $6.07 and a 52-week high of $18.08. On the Street’s front, the average 12-month analyst price target for the stock is $12.00, marking a -5.88% potential downside from current levels. In a report released today, Morgan Stanley analyst David Risinger maintained a Sell rating on TEVA, with a price target of $13.00, which represents a slight upside potential from current levels. Separately, yesterday, Piper Sandler’s David Amsellem maintained a Hold rating on the stock and has a price target of $10.00.

See today’s analyst top recommended stocks >>

Marathon Oil is down -4.49% in midday trading to $10.63. Shares opened today at $11.13. The company has a 52-week low of $10.61 and a 52-week high of $18.93. On the Street’s front, the average 12-month analyst price target for the stock is $17.38, marking a 56.15% potential upside from current levels. In a report released yesterday, Credit Suisse analyst William Featherston maintained a Buy rating on MRO, with a price target of $15.00, which represents a potential upside of 35% from where the stock is currently trading. Separately, on the same day, Siebert Williams Shank & Co., LLC’s Gabriele Sorbara reiterated a Hold rating on the stock and has a price target of $14.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.